Matching articles for "Xocova"
Ensitrelvir (Xocova) for Post-Exposure Prophylaxis of COVID-19
The FDA has approved ensitrelvir ( Xocova – Shionogi), a SARS-CoV-2 main protease inhibitor, for postexposure prophylaxis of COVID-19 in patients ≥12 years old who had contact with an infected individual.…
Med Lett Drugs Ther. 2026 Jul 20; 68(1759):113-4 doi:10.58347/tml.2026.1759a
The FDA has approved ensitrelvir ( Xocova – Shionogi), a SARS-CoV-2 main protease inhibitor, for postexposure prophylaxis of COVID-19 in patients ≥12 years old who had contact with an infected individual. Ensitrelvir is the first oral antiviral drug to be approved in the US for this indication. The parenteral monoclonal antibody combinations bamlanivimab and etesevimab and casirivimab and imdevimab (REGEN-COV) are no longer authorized for postexposure prophylaxis of COVID-19 in the US.
